Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Aug;34(8):1597–1599. doi: 10.1128/aac.34.8.1597

In vitro susceptibilities of oral pigmented Bacteroides species to trospectomycin and other selected antimicrobial agents.

C C Johnson 1, M Wendeler 1, M E Levison 1
PMCID: PMC171880  PMID: 2145801

Abstract

The in vitro activity of trospectomycin against 97 clinical isolates of oral pigmented Bacteroides species was compared with the activities of five other antimicrobial agents. At 4 micrograms/ml, more than 90% of isolates were inhibited by trospectomycin. Overall, strains that produced beta-lactamase (n = 41) were more resistant to trospectomycin, penicillin G, cefoxitin, piperacillin, and tetracycline but not to clindamycin. In this study, trospectomycin had excellent in vitro activity against oral pigmented Bacteroides species.

Full text

PDF
1597

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edson R. S., Rosenblatt J. E., Lee D. T., McVey E. A., 3rd Recent experience with antimicrobial susceptibility of anaerobic bacteria: increasing resistance to penicillin. Mayo Clin Proc. 1982 Dec;57(12):737–741. [PubMed] [Google Scholar]
  2. Gabay E. L., Sutter V. L., Finegold S. M. Rapid beta-lactamase testing in bacteroides. J Antimicrob Chemother. 1981 Nov;8(5):413–416. doi: 10.1093/jac/8.5.413. [DOI] [PubMed] [Google Scholar]
  3. Jacobus N. V., Tally F. P. Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species. Antimicrob Agents Chemother. 1988 Apr;32(4):584–586. doi: 10.1128/aac.32.4.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Peeters M., Van Dyck E., Piot P. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1984 Oct;26(4):608–609. doi: 10.1128/aac.26.4.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Sanson-Le Pors M. J., Casin I. M., Thebault M. C., Arlet G., Perol Y. In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi. Antimicrob Agents Chemother. 1986 Sep;30(3):512–513. doi: 10.1128/aac.30.3.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Zurenko G. E., Yagi B. H., Vavra J. J., Wentworth B. B. In vitro antibacterial activity of trospectomycin (U-63366F), a novel spectinomycin analog. Antimicrob Agents Chemother. 1988 Feb;32(2):216–223. doi: 10.1128/aac.32.2.216. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES